Merck KGaA Signed a Master Collaboration Agreement with Indivumed to Utilize nRavel's Capabilities for the Company's Drug Development Activities

First Pharma Companies Sign Collaboration Agreements, Announce Utilization of Novel Platform

HAMBURG, Germany, June 2, 2021 /PRNewswire/ -- Indivumed GmbH ("Indivumed") today announced that Merck KGaA, Darmstadt, Germany signed a master collaboration agreement with Indivumed to utilize nRavel's capabilities for the company's drug development activities.

"The nRavelTM platform puts Indivumed ahead of all other AI-driven drug development platforms. The combination of proprietary AI-integrated analytical tools with unique multi-omics data sets from thousands of patients delivers an unprecedented understanding of cancer biology in individual patients and provides truly novel targets for highly efficient and rapid drug development, " said Prof. Dr. Hartmut Juhl, CEO and Founder of Indivumed. "We look forward to partnering with Merck KGaA, Darmstadt, Germany, who recognized our nRavelTM platform as an exciting new solution for drug development."

The nRavelTM platform currently includes six toolboxes (immuno-oncology, pathways and signaling, biomarkers, genomics, signatures, clinical analytics), each containing specific applications designed to improve the efficiency and effectiveness of cancer research and drug development projects. Indivumed plans to continue adding applications to each toolbox in the coming months.

About Indivumed
Driven by our mission to unveil the complex mechanisms of cancer and advance precision oncology, Indivumed combines the world's most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise and AI-integrated advanced analytics. Our global clinical network enables us to collect and analyze thousands of patient samples using a standardized approach to ensure biospecimen quality across three business units – IndivuServ, IndivuTest, and IndivuType. The unparalleled depth and quality of our data – coupled with our robust product and service offerings – gives us the ability to obtain novel insights and accelerate cancer research. For more information, visit

Media Contact:
Patrick Renegar
W: 703-519-1600 Ext. 104
[email protected]

SOURCE Indivumed

Related Links